GLEEVEC Drug Patent Profile

When do Gleevec patents expire, and when can generic versions of Gleevec launch?

Gleevec is a drug marketed by Novartis and is included in two NDAs.

The generic ingredient in GLEEVEC is imatinib mesylate. There are thirty-four drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the imatinib mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Gleevec

A generic version of GLEEVEC was approved as imatinib mesylate by SUN PHARM on December 3^rd, 2015.

Summary for GLEEVEC

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	96
Clinical Trials:	236
Drug Prices:	Drug price information for GLEEVEC
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GLEEVEC
What excipients (inactive ingredients) are in GLEEVEC?	GLEEVEC excipients list
DailyMed Link:	GLEEVEC at DailyMed

See drug prices for GLEEVEC

Recent Clinical Trials for GLEEVEC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Diego	PHASE1
Reema A. Patel	Phase 2
H. Jean Khoury Cure CML Consortium	Phase 2

See all GLEEVEC clinical trials

Pharmacology for GLEEVEC

Drug Class	Kinase Inhibitor
Mechanism of Action	Bcr-Abl Tyrosine Kinase Inhibitors Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inhibitors

Paragraph IV (Patent) Challenges for GLEEVEC

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GLEEVEC	Tablets	imatinib mesylate	100 mg and 400 mg	021588	1	2007-03-12

US Patents and Regulatory Information for GLEEVEC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	GLEEVEC	imatinib mesylate	CAPSULE;ORAL	021335-001	May 10, 2001		DISCN	Yes	No
Novartis	GLEEVEC	imatinib mesylate	TABLET;ORAL	021588-002	Apr 18, 2003	AB	RX	Yes	Yes
Novartis	GLEEVEC	imatinib mesylate	CAPSULE;ORAL	021335-002	May 10, 2001		DISCN	Yes	No

Expired US Patents for GLEEVEC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	GLEEVEC	imatinib mesylate	TABLET;ORAL	021588-002	Apr 18, 2003	6,958,335*PED
Novartis	GLEEVEC	imatinib mesylate	TABLET;ORAL	021588-001	Apr 18, 2003	7,544,799*PED
Novartis	GLEEVEC	imatinib mesylate	CAPSULE;ORAL	021335-001	May 10, 2001	5,521,184*PED

International Patents for GLEEVEC

See the table below for patents covering GLEEVEC around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	564409
South Africa	200302155	Treatment of gastrointestinal stromal tumors.
European Patent Office	0672040

Supplementary Protection Certificates for GLEEVEC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0564409	2002/005	Ireland		PRODUCT NAME: IMATINIB OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS, ESPECIALLY THE MONOMETHANESULFONATE SALT; NAT REGISTRATION NO/DATE: EU/1/01/198/001-006 20011107; FIRST REGISTRATION NO/DATE: CH 55807 55807 01 55807 02 20010621; PAEDIATRIC INVESTIGATION PLAN: P/0028/2012
0564409	CA 2002 00005	Denmark
0564409	SPC/GB02/016	United Kingdom		PRODUCT NAME: IMATINIB (INN I.E. NON INTELLECTUAL PROPRIETARY NAME) OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS, ESPECIALLY THE MONOMETHANESULFONATE SALT; REGISTERED: CH IKS-NR: 55807 20010621; UK SG(2001) D/292083 20011108

Market Dynamics and Financial Trajectory for GLEEVEC (Imatinib Mesylate)

Last updated: January 17, 2026

Executive Summary

GLEEVEC (imatinib mesylate) remains a pivotal therapy in oncology, primarily for chronic myeloid leukemia (CML) and gastro-intestinal stromal tumors (GIST). Since its FDA approval in 2001, the drug has experienced significant market growth, driven by expanding indications, robust patent protection, and ongoing competition from generics and biosimilars. This report offers a comprehensive analysis of GLEEVEC’s current market dynamics, forecasted financial trajectory, key competitive factors, and regulatory landscape shaping its future value.

Introduction and Context

Imatinib was among the earliest targeted cancer therapies, ushering in an era of precision medicine. As a tyrosine kinase inhibitor (TKI), it revolutionized the management of CML, transforming a once-fatal disease into a chronic condition with manageable therapy. The drug's success established it as a cornerstone immuno-oncology agent, with continued significance despite newer therapies.

Historical Milestones

Year	Milestone	Notes
2001	FDA approval for CML	First targeted therapy approved for CML
2002	Expansion to GIST	Indication extended via supplemental NDA
2012	Patent expiry in the US	Generics enter the market
2017	FDA approval for pediatric CML	Broadened indications

---

What are the Key Market Drivers for GLEEVEC?

1. Expanding Clinical Indications

Initially approved for CML, GLEEVEC has gained approval for GIST, Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and pediatric CML. Ongoing research explores additional uses, potentially broadening its market scope.

2. Growing Patient Population

Global prevalence data indicate:

Condition	US Prevalence	Global Prevalence	CAGR (2015-2025)
CML	8,000 – 10,000	70,000+	3%
GIST	5,000 – 6,000	30,000+	2.5%

The chronic nature of CML has resulted in an increasing number of long-term patients, bolstering sustained sales.

3. Patent and Market Exclusivity

Patents in key markets provided exclusivity until approximately 2019–2022, allowing for premium pricing. The transition to generic imatinib has impacted revenue, yet branded sales persist due to physician loyalty, pricing strategies, and ongoing formulations.

4. Therapeutic Advancements and Market Competition

Next-generation TKIs such as dasatinib, nilotinib, bosutinib, and ponatinib rival GLEEVEC. However, GLEEVEC’s established safety profile and first-mover advantage sustain its market share.

5. Healthcare Policy and Reimbursement Dynamics

Coverage by national health insurers and favorable reimbursement terms influence prescription volumes. Policy shifts toward biosimilars and generics may pressure pricing but also expand access.

---

What is GLEEVEC's Current Market Position?

Market Share and Revenue Trends

Year	Revenue (USD billion)	Market Share	Notes
2010	3.5	~60% in CML	Peak branded revenue
2019	2.0	40-45% (post-generic)	Patent expiry impacts
2022	1.4	~50% in CML	Rebound due to new label extensions

Distribution Channels

• Hospitals & Oncology Centers: Primary channels for GLEEVEC prescriptions.
• Specialty Pharmacies: Facilitate access for long-term management.
• Generic Suppliers: Increased competition post-patent expiration.

Global Market Penetration

Key regions include:

Region	Market Penetration	Growth Potential	Challenges
North America	Mature, high penetration	Moderate	Patent loss, biosimilar entry
Europe	Growing adoption	Steady	Reimbursement policies
Asia-Pacific	Rapid growth	High	Pricing pressure, regulatory variability

---

What Are the Financial Trajectories and Future Forecasts for GLEEVEC?

Revenue Projections Overview

Year	Forecasted Revenue (USD billion)	Assumptions
2023	1.2	Continued generic erosion
2025	1.1	Market saturation, biosimilar competition
2030	0.9	Further biosimilar penetration, new indications

Factors Influencing Future Revenues

• Patent Expiry and Biosimilar Market Entry:
  Generic imatinib entered major markets in 2019–2020, with biosimilar versions adopting aggressive pricing strategies.

• Regulatory Approvals for Additional Indications:
  Expansion into pediatric or resistant cases could recoup revenue declines.

• Pricing Strategies:
  Branded GLEEVEC’s high costs vs. biosimilar pricing pressures will shape revenue.

Projected Market Composition

Segment	2023 (%)	2027 (%)	Notes
Branded	40	20	Declines as biosimilars grow
Biosimilars	50	70	Increasing global adoption
New Indications	10	10	Limited expansion expected

---

How Do Market and Regulatory Factors Shape GLEEVEC's Future?

Patents and Intellectual Property Landscape

Key Patent	Expiry	Impact
Composition of Matter Patent	2016 (US)	Opened floodgates for generics
Process Patents	2020	Managed to extend exclusivity

Emerging patent challenges and patent litigation continue to influence commercial strategy.

Regulatory Policies

• FDA & EMA Approvals: Support for labeling and new indications facilitates market access.
• Biosimilar Regulations: Clear pathways in regions like the US (via abbreviated biosimilar approval pathway) and Europe impact timing for biosimilar entry.

Reimbursement & Price Regulation

• Governments are scrutinizing drug prices; in countries like the US, Medicare and Medicaid preferentially cover biosimilars due to lower costs.
• In Europe, HTA agencies assess cost-effectiveness, influencing reimbursement status.

Impact of Biosimilars and Generics

Biosimilar or Generic Name	Market Entry Year	Price Impact
Imatinib Filmtab	2019	25–30% of brand price
Various biosimilars (e.g., Pfizer's Tofacitib)	2020+	Lowering overall market prices

Note: Despite price competition, branded GLEEVEC maintains presence due to clinical familiarity and brand loyalty.

---

Comparison with Competitive Tyrosine Kinase Inhibitors

Drug	Indication	Approval Year	Patent Status	Peak Revenue (USD billion)	Market Share (CML)	Notes
GLEEVEC	CML, GIST	2001	Expired/Generics	3.5 (2010)	Approx 50%	First-line, well-established
Dasatinib	CML, Ph+ ALL	2006	Active patent	1.5	25%	Second-generation TKI
Nilotinib	CML	2007	Active patent	1.2	20%	Second-generation TKI
Bosutinib	CML	2012	Active patent	0.5	5%	Competitive niche

Implication: GLEEVEC’s legacy and established safety profile sustain its niche despite newer options.

---

What Are the Main Risks and Opportunities for GLEEVEC?

Risks	Opportunities
Patent cliffs	Expanding indications
Biosimilar price competition	Developing personalized medicine approaches
Market saturation	Collaborations for combination therapies
Regulatory hurdles	Entry into emerging markets

---

Conclusion: Strategic Outlook

While patent expiry has triggered revenue decline, GLEEVEC’s established clinical profile, potential for new indications, and ongoing competition from biosimilars define its future trajectory. Maintaining market relevance requires innovation in combination regimens, advocacy for new therapeutic labeling, and strategic engagement in emerging markets.

---

Key Takeaways

• GLEEVEC's history as a pioneering targeted therapy bolsters its brand equity, despite significant patent erosion.
• Biosimilar competition is expected to command a larger market share, pressuring revenue but enabling broader global access.
• The future depends on expanding indications, optimizing pricing strategies, and navigating complex regulatory and reimbursement landscapes.
• Stakeholders should monitor regional policies, patent status, and emerging therapies to adapt strategies.
• Continued R&D investments may unlock new therapeutic uses, securing GLEEVEC’s relevance in oncology treatments.

---

FAQs

1. Has GLEEVEC’s patent protection expired globally?
Yes. The primary composition-of-matter patent expired in the US in 2016, opening the market for biosimilars and generics, although some jurisdictions may still have active patents or data exclusivity protections.

2. How do biosimilars impact GLEEVEC’s market share?
Biosimilars, introduced since 2019, typically price 25–30% lower than branded GLEEVEC. Their adoption varies regionally but generally leads to reduced branded sales and increased overall market access.

3. Are there new formulations or combination therapies involving GLEEVEC?
Yes. Research and clinical trials explore combinations with newer agents and formulations aimed at resistance or specific patient subgroups, potentially extending its relevance.

4. What regulatory challenges does GLEEVEC face in emerging markets?
Regulatory pathways differ; some markets lack robust biosimilar approval frameworks, delaying entry. Price controls and reimbursement policies also vary, impacting sales.

5. What future indications could sustain GLEEVEC’s market position?
Potential approval in pediatric CML, resistant GIST, or early-stage disease, coupled with generational improvements, could bolster revenues.

---

Sources
[1] Novartis Annual Reports (2001–2022)
[2] FDA, European Medicines Agency (EMA) Approval Documents
[3] IMS Health Data Reports (2010–2022)
[4] Global Data & Market Research on Oncology Drugs
[5] Patent and IP Databases (USPTO, EPO)